Solubility Enhancement Services Information Sheet
Thursday, May 19, 2016
Not addressing solubility at the beginning of development can put your timeline and your molecule at risk. As many as 60-90% of drug candidates have bioavailability challenges and 37% will fail in phase I-III clinical trials as a result.
Patheon Solubility Enhancement Services approaches BCS II drug substance solubility challenges in a fundamentally different way. By evaluating your molecule’s physiochemical characteristics through molecular modeling in advance, we identify the solubility enhancement technologies most likely to be effective before any work is done or API is wasted, which helps eliminate rework and worry later on, saving you time and money.
Please complete the short form below to download this asset.